WCLC: As­traZeneca builds case for grow­ing ADC pipeline with dou­ble wins in ad­vanced lung can­cer

As part of its hard piv­ot to on­col­o­gy in re­cent years, As­traZeneca made a big bet on next-gen can­cer fight­ers with a multi­bil­lion-dol­lar deal in ear­ly 2019 with Dai­ichi Sankyo for its an­ti­body-drug con­ju­gates. The orig­i­nal­ly tar­get­ed ther­a­py has al­ready made good on its mar­ket promise, and now As­traZeneca has high hopes for an­oth­er.

As­traZeneca’s TROP2 tar­get­ing datopotam­ab derux­te­can post­ed 32 com­plete or par­tial re­spons­es in metasta­t­ic non-small cell lung can­cer and an ad­di­tion­al five that were still too ear­ly to con­firm, ac­cord­ing to da­ta from the Phase I TRO­PI­ON-Pan­Tu­mor01 tri­al pre­sent­ed Fri­day at the vir­tu­al World Con­gress on Lung Can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER